Skip to main content
Funded Studies

Jonas Hannestad, MD, PhD

Chief Medical Officer at Gain Therapeutics

Location: Bethesda, MD United States

Dr. Hannestad has 25 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations with a special emphasis on translational medicine and early clinical development in neurodegeneration. Dr. Hannestad is currently Chief Medical Officer at Gain Therapeutics, and previously held clinical development positions at Tranquis Therapeutics, Capacity Bio, Alkahest, Denali Therapeutics, UCB and BMS. He has worked on multiple Parkinson’s programs, including GBA, LRRK2, adenosine 2A, and alpha-synuclein. He received his MD from the University of Oviedo and a PhD from the University of Messina, and completed residency training in internal medicine and psychiatry at Duke University and Yale University.


Associated Grants

  • Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic

    2019


  • Safety and Tolerability of GRF6021 Infusions in People with Parkinson's Disease and Cognitive Impairment

    2018


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.